MEDIPOST announced that it has obtained a patent for its core technology for treating Alzheimer’s disease in six European countries.

The title of this patent is ‘Use of ICAM-1 for prevention or treatment of neurological diseases’ and MEDIPOST has obtained the patent simultaneously in the UK, Germany, France, Italy, Spain and Switzerland.

When the stem cells from cord blood are injected to patients with Alzheimer’s disease, ‘ICAM-1’ in the stem cells induce the breakdown of and elimination of amyloid-β (Aβ) plaques which are causative agents of Alzheimer’s disease.

This patented technology will be used during the most important treatment process for Alzheimer’s disease patients and also be used for developing the Alzheimer’s disease treatment drug, NEUROSTEM^® currently being developed by MEDIPOST.